Requirement of P53 Targets in Chemosensitization of Colonic Carcinoma to Death Ligand Therapy

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.2435285100
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

Immunoprophylaxis and Therapy of Grafted Rat Colonic Carcinoma.

Gut
Gastroenterology
1977English

Colonic Endometriosis Mimicking Colonic Carcinoma

The Internet Journal of Pathology
2009English

A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma in Vivo

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Studies of Colonic Carcinoma Antigens

Gut
Gastroenterology
1971English

Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers

British Journal of Cancer
Cancer ResearchOncology
2015English

Increased Programmed Death Ligand-1 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients

OncoTargets and Therapy
OncologyPharmacology
2016English

Heparin-Degrading Sulfatases in Hepatocellular Carcinoma: Roles in Pathogenesis and Therapy Targets

Future Oncology
MedicineCancer ResearchOncology
2008English

Targets of the P53-Related Transcription Factors

Nature Genetics
Genetics
2001English

639. Combination Therapy of Bufalin and rAd-p53 for the Treatment of Hepatocellular Carcinoma in Vivo

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy